secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001213900-23-064516
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio Q2 net loss $6.5M; XPro™ AD trial enrolling; INKmune™ IND cleared
----------------------------------------------------------------------------

- Net loss $6.5M vs $6.8M YoY; R&D $4.1M; G&A $2.3M; cash $47.8M at June 30, 2023.
- XPro™ Phase II Early AD trial enrolling; FDA pathway to lift clinical hold before end-2023.
- New MRI gray matter biomarker data from XPro™ presented at AAIC July 2023.
- INKmune™ IND cleared for Phase I/II in mCRPC; first patient enrollment expected Q4 2023.
- Top-line XPro™ AD results anticipated late 2024; LAUREL trial opened third site in Greece.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390023064516/0001213900-23-064516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390023064516/ea183062-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-064516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer